SUZHOU ZELGEN BIOPHARMACEU

Suzhou Zelgen Biopharma’s shares remain flat at CNY 103.75, down 14.26% month‑on‑month, while its 27.2 bn CNY market cap and 200‑day SMA of CNY 113.95 highlight a key biotech stock to watch in China’s growing pharma sector.

Suzhou Zelgen Biopharma’s shares hold steady at CNY 100.44, amid flat trading and a 200‑day SMA below price—watch for pipeline milestones that could spark a breakout.

SuZhou Zelgen Biopharma: stock flat at CNY 102.62, but a $1 M AbbVie milestone fuels its oncology pipeline, signalling growth potential in China’s biotech market.